Cortecs' Oral Calcitonin Nears First Filing
UK-based Cortecs looks on target to get the first product from its coreoral protein delivery program, Macritonin (salmon calcitonin), on the market for the treatment of osteoporosis within the next 12 to 18 months.
The last hurdle for the company is the results of a European Phase II/III study of Macritonin, which should undergo statistical analysis in April. If the results are positive, Cortecs plans to make its first marketing approval application in Europe in the same month.
Cortecs is looking to show that Macritonin is at least equivalent to the intranasal form of calcitonin, Novartis' Miacalcic, which is showing an extremely healthy rate of growth. Miacalcic has captured 32% of all new prescriptions for post-menopausal osteoporosis since its launch, and is now making sales of around $270 million a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze